Invention Grant
- Patent Title: Prodrugs of HIV reverse transcriptase inhibitors
-
Application No.: US15300405Application Date: 2015-03-27
-
Publication No.: US10004740B2Publication Date: 2018-06-26
- Inventor: Christopher S. Burgey , Jeffrey F. Fritzen , Jaume Balsells , Mehul Patel
- Applicant: Merck Sharp & Dohme Corp.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Carol S. Quagliato; John C. Todaro
- International Application: PCT/US2015/022868 WO 20150327
- International Announcement: WO2015/153304 WO 20151008
- Main IPC: C07D403/06
- IPC: C07D403/06 ; C07D237/22 ; C07D239/47 ; A61K31/501 ; A61K31/506 ; A61K31/513 ; A61P31/18 ; A61K45/06

Abstract:
Compounds of Formula I are described: wherein R1 and R2 are defined herein. The compounds of Formula I are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV, and the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
Public/Granted literature
- US20170173015A1 PRODRUGS OF HIV REVERSE TRANSCRIPTASE INHIBITORS Public/Granted day:2017-06-22
Information query